FDA lifts partial hold on Curis anticancer agent
This article was originally published in Scrip
Executive Summary
Shares of Curis jumped 12.7% on 31 March after the company said the FDA was removing the partial clinical hold placed last November on the firm's Phase I trial of CUDC-427, a small molecule antagonist of oral inhibitor of apoptosis proteins.